Larry Wood Net Worth

The estimated Net Worth of Larry L Wood is at least $18.5 Million dollars as of 3 May 2024. Mr. Wood owns over 6,675 units of Edwards Lifesciences Corp stock worth over $15,016,433 and over the last 16 years he sold EW stock worth over $152,042. In addition, he makes $3,289,280 as Corporate Vice President - Transcatheter Aortic Valve Replacement at Edwards Lifesciences Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Wood EW stock SEC Form 4 insiders trading

Larry has made over 105 trades of the Edwards Lifesciences Corp stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 6,675 units of EW stock worth $455,569 on 3 May 2024.

The largest trade he's ever made was exercising 90,000 units of Edwards Lifesciences Corp stock on 18 August 2014 worth over $2,832,300. On average, Larry trades about 8,224 units every 35 days since 2008. As of 3 May 2024 he still owns at least 220,021 units of Edwards Lifesciences Corp stock.

You can see the complete history of Mr. Wood stock trades at the bottom of the page.

Larry Wood biography

Larry L. Wood serves as Corporate Vice President - Transcatheter Aortic Valve Replacement of the Company. Mr. Wood has been Corporate Vice President, Transcatheter Aortic Valve Replacement (“TAVR”) since 2007. Under his leadership, Edwards has experienced extraordinary growth in the global TAVR business, and the Edwards SAPIEN heart valve has won numerous awards, including the Prix Galien “Best Medical Technology Product” award. Most recently prior to his current role, from March 2004 to February 2007, he served as Vice President and General Manager, Percutaneous Valve Interventions. Mr. Wood has more than 30 years of experience in the medical technology industry at both Edwards and Baxter Healthcare Corporation in positions including manufacturing management, regulatory affairs and strategic and clinical marketing, primarily for the surgical heart valve therapy business. Mr. Wood is also a passionate supporter of the United Way Orange County’s Destination Graduation Program which encourages at-risk high school students to graduate and pursue higher education.

What is the salary of Larry Wood?

As the Corporate Vice President - Transcatheter Aortic Valve Replacement of Edwards Lifesciences Corp, the total compensation of Larry Wood at Edwards Lifesciences Corp is $3,289,280. There are 2 executives at Edwards Lifesciences Corp getting paid more, with Michael Mussallem having the highest compensation of $11,521,000.

How old is Larry Wood?

Larry Wood is 54, he's been the Corporate Vice President - Transcatheter Aortic Valve Replacement of Edwards Lifesciences Corp since 2018. There are 18 older and 2 younger executives at Edwards Lifesciences Corp. The oldest executive at Edwards Lifesciences Corp is William Link, 74, who is the Independent Director.

What's Larry Wood's mailing address?

Larry's mailing address filed with the SEC is ONE EDWARDS WAY, , IRVINE, CA, 92614.

Insiders trading at Edwards Lifesciences Corp

Over the last 21 years, insiders at Edwards Lifesciences Corp have traded over $94,964,396 worth of Edwards Lifesciences Corp stock and bought 47,398 units worth $3,992,090 . The most active insiders traders include Michael A Mussallem, Donald E Jr Bobo, and Steven R Loranger. On average, Edwards Lifesciences Corp executives and independent directors trade stock every 8 days with the average trade being worth of $1,126,057. The most recent stock trade was executed by Donald E Jr Bobo on 11 September 2024, trading 5,000 units of EW stock currently worth $226,400.

What does Edwards Lifesciences Corp do?

edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.

Complete history of Mr. Wood stock trades at Edwards Lifesciences Corp

Edwards Lifesciences Corp executives and stock owners

Edwards Lifesciences Corp executives and other stock owners filed with the SEC include:

• Michael Mussallem,
  Chairman of the Board, Chief Executive Officer
• Scott Ullem,
  Chief Financial Officer, Corporate Vice President
• Larry Wood,
  Corporate Vice President - Transcatheter Aortic Valve Replacement
• Donald Bobo,
  Corporate Vice President - Strategy and Corporate Development
• Catherine Szyman,
  Corporate Vice President - Critical Care
• Jean-Luc Lemercier,
  Corporate Vice President - EMEA (Europe, Middle East and Africa)
• Michael A. Mussallem,
  Chairman & CEO
• Jean-Luc Lemercier,
  Corp. VP of Europe, Middle East, Africa, Canada & Latin America
• Scott B. Ullem,
  Corp. VP & CFO
• Larry L. Wood,
  Corp. VP of Transcatheter Aortic Valve Replacement
• Donald E. Bobo Jr.,
  Corp. VP of Strategy & Corp. Devel.
• Heisz Stone,
  Independent Director
• William Link,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Steven Loranger,
  Independent Director
• Nicholas Valeriani,
  Independent Director
• Martha Marsh,
  Lead Independent Director
• Paul LaViolette,
  Director
• Ramona Sequeira,
  Director
• Daveen Chopra,
  Corporate Vice President - Surgical Structural Heart
• Huimin Wang,
  Corporate Vice President - Japan, Asia and Pacific
• Christine Z. McCauley,
  Corp. VP of HR
• Dirksen J. Lehman,
  Corp. VP of Public Affairs
• Arnold A. Pinkston,
  Corp. VP & Gen. Counsel
• Mark Wilterding,
  VP of Investor Relations
• Dr. Todd J. Brinton,
  Corp. VP of Advanced Technology & Chief Scientific Officer
• Patrick B Verguet,
  CVP, Europe
• John T Cardis,
  Director
• Schack Wesley W Von,
  Director
• Daniel J. Lippis,
  CVP, JAPAC
• Carlyn D Solomon,
  CVP, Critical Care & Vascular
• David E I Pyott,
  Director
• Michael R Bowlin,
  Director
• Bruce P Garren,
  Corp VP, Gen Counsel & Secty
• Barbara J Mcneil,
  Director
• Robert Alexander Ingram,
  Director
• John H Jr Kehl,
  Corp VP, Strategy & Bus Dev
• Thomas M Abate,
  CVP, CFO and Treasurer
• Christine Z Mc Cauley,
  CVP, Human Resources
• Robert C Reindl,
  Corp VP, Human Resources
• Aimee S Weisner,
  CVP, General Counsel
• Vernon R Jr Loucks,
  Director
• Paul C Redmond,
  CVP, CardioVations Surgcl Sys
• Corinne H Nevinny,
  CVP, Chief Financial Officer
• Philip M Neal,
  Director
• Stuart L Foster,
  Corp VP, Technology/Discovery
• John Alexander Martin,
  CVP, North America
• Anita Bessler,
  Corp VP, Global Franchise Mgmt
• Randel William Woodgrift,
  Corp VP, Manufacturing Ops
• J Randall Nelson,
  Corp VP, North America
• David T Feinberg,
  Director
• Robert W.A. Sellers,
  SVP, Corporate Controller
• Bernard J Zovighian,
  CEO
• Wayne Markowitz,
  GM & SVP, Surgical
• Leslie C. Davis,
  Director